Silo Pharma Secures EPO Patent Approval for 5-HT4 Therapy

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Apr 06 2026

0mins

SILO+1.18%

Should l Buy SILO?

Source: Newsfilter

Patent Approval Milestone: Silo Pharma has received a communication from the European Patent Office (EPO) indicating its intent to grant a patent for the use of 5-HT4 receptor agonists in preventing stress-related disorders, marking a significant advancement in the company's global intellectual property position and expected to enhance its strategic positioning in major European markets.
Innovative Treatment Approach: The patent covers methods for preventing stress-induced fear and depressive-like behaviors using selected 5-HT4 receptor agonists, representing a proactive treatment strategy that targets pathways associated with stress resilience, potentially transforming the treatment landscape for stress-related disorders and addressing urgent market needs.
Significant Market Potential: CEO Eric Weisblum emphasized that stress-related disorders represent a massive and underserved market, and the patent's approval will facilitate the advancement of the company's pipeline in this area, thereby enhancing its competitive edge.
Global Strategic Expansion: The company is evaluating Unitary Patent protection and key national validations to maximize geographic coverage and long-term value, further solidifying its leadership position in the global mental health and stress-related treatment sectors.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy SILO?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on SILO

About SILO

Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

SPC-15 PTSD Program Aligns with Federal Push for Mental Health Therapies

4 hours agoNewsfilter

Policy Acceleration: On April 18, 2026, President Trump signed an executive order directing multiple U.S. agencies to expedite research into psychedelic therapies for mental health, indicating a national focus that could create a more favorable regulatory environment for Silo Pharma's SPC-15 program.
Innovative Treatment Approach: SPC-15, designed as a novel 5-HT4 receptor agonist, targets prophylactic treatment for PTSD and utilizes rapid nose-to-brain delivery to enhance therapeutic effects and patient compliance, potentially revolutionizing mental health treatment outcomes.
Significant Market Opportunity: The global mental health therapeutics market is expanding, with PTSD affecting millions annually; the growing acceptance of psychedelic-assisted therapies may unlock new treatment paradigms and commercial opportunities, positioning Silo Pharma favorably in this evolving landscape.
Clear R&D Strategy: Silo Pharma has licensed intellectual property for SPC-15 from Columbia University and is preparing for FDA IND engagement, demonstrating a strategic focus on drug delivery and clinical development aimed at leveraging evolving regulatory frameworks to accelerate innovation.

Trump Signs Executive Order to Accelerate Psychedelic Research

3 hours agostocktwits

Funding Support: Trump signed an executive order allocating $50 million for psychedelic research aimed at accelerating studies on PTSD treatments, potentially paving the way for future drug reclassification.
Clearmind Drug Progress: Clearmind Medicines' CMND-100 met its primary goal in early-stage trials, demonstrating strong safety with no serious side effects reported at higher doses, likely enhancing its market competitiveness.
Market Reaction: Clearmind's shares surged nearly 65% in pre-market trading, marking its largest intraday gain since August 2022, reflecting strong investor interest in the therapeutic potential of psychedelics.
Silo Pharma Development: Silo Pharma is developing SPC-15, a nasal spray designed to prevent PTSD, utilizing a fast nose-to-brain delivery method, and is expected to benefit from a more favorable regulatory environment.

Silo Pharma Secures Patent for PTSD Therapy

Apr 07 2026stocktwits

Patent Grant: Silo Pharma has been awarded a patent for the application titled 'Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,' further solidifying the company's position in the mental health market, which is considered a 'massive and underserved market.'
Market Reaction: Following the European Patent Office's indication to grant the patent, Silo Pharma's shares surged over 85% in premarket trading on Tuesday, reflecting strong investor confidence and market anticipation for the new therapy.
Innovative Therapy: This therapy differs from traditional PTSD treatments by focusing on enhancing stress resilience rather than managing symptoms post-trauma, indicating a strategic shift in the company's treatment approach that may attract more attention and investment.
Global IP Expansion: Silo Pharma described the patent grant as a 'high-value milestone' that will strengthen its global intellectual property position, aiding the company's efforts to maximize geographic coverage and long-term value.

Silo Pharma Secures European Patent for Stress Disorder Prevention

Apr 07 2026NASDAQ.COM

Patent Progress: Silo Pharma has received a patent allowance from the European Patent Office for an innovative approach to preventing stress-related disorders, marking a significant milestone in the biopharmaceutical sector that is expected to enhance its intellectual property portfolio and market competitiveness.
Therapeutic Potential: The patent focuses on preventing stress-induced fear and depressive behaviors through the 5-HT4 receptor pathway, representing a shift from symptom management to prevention, which could open new avenues in mental health treatment.
Diversified Pipeline: Silo Pharma is advancing several programs, including SPC-15 for PTSD, SP-26 for fibromyalgia, and SPC-14 for neuroinflammation, with multiple data releases expected in 2026, showcasing the company's extensive commitment to mental health.
Broad Market Outlook: With increasing global attention on mental health, Silo Pharma's patent allowance positions it to lead in CNS therapeutics, potentially reshaping how clinicians and patients approach the management of psychiatric disorders.